Thomas Perone
Plus aucun poste en cours
Fortune : 9 952 $ au 30/06/2024
Profil
Thomas M.
Perone worked as a Senior Director-Legal at ImClone LLC from 2001 to 2006.
He then served as Vice President & Assistant Corporate Secretary at Celgene Corp.
from 2006 to 2018.
Prior to that, he was an Associate Attorney at Proskauer Rose LLC.
Currently, he is the Secretary, Senior VP & General Counsel at Ovid Therapeutics, Inc. Mr. Perone completed his undergraduate degree at Rutgers State University of New Jersey in 1986.
He obtained an MBA from Fairleigh Dickinson University in 1993.
In 1997, he graduated from Seton Hall University School of Law.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OVID THERAPEUTICS INC.
0,02% | 09/04/2024 | 12 942 ( 0,02% ) | 9 952 $ | 30/06/2024 |
Anciens postes connus de Thomas Perone
| Sociétés | Poste | Fin |
|---|---|---|
| OVID THERAPEUTICS INC. | Compliance Officer | 11/07/2024 |
| CELGENE | Conseiller Juridique Général | - |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Conseiller Juridique Général | 01/04/2006 |
| Proskauer Rose LLC | Corporate Officer/Principal | - |
Formation de Thomas Perone
| Rutgers State University of New Jersey | Undergraduate Degree |
| Fairleigh Dickinson University | Masters Business Admin |
| Seton Hall University School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| OVID THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
| Proskauer Rose LLC |
